Teniposide

CHEMBL452231 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
656.7 g/mol
LogP
1.2
Phase
4

Teniposide is a semisynthetic epipodophyllotoxin derived from podophyllotoxin that inhibits topoisomerase II, causing DNA double-strand breaks and cell cycle arrest at the G2/M phase. It is used in the treatment of childhood acute lymphoblastic leukemia and is active against brain tumors, bladder cancer, and breast cancer. Its antitumor activity is related to stabilization of the cleavable complex between topoisomerase II and DNA, leading to irreversible DNA strand breaks.

Молекулярная масса

656,7000 g/mol

LogP

1,20

TPSA

189,00 Ų

Правило пяти Липинского

Не соответствует

Терапевтические области

Механизм действия

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O

InChI

InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1

Molecular Formula

C32H32O13S

HBD / HBA

3 / 14

Вращаемые Связи

6

Тяжёлые Атомы

46

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Teniposide is a semisynthetic epipodophyllotoxin derived from podophyllotoxin that inhibits topoisomerase II, causing DNA double-strand breaks and cell cycle arrest at the G2/M phase. It is used in the treatment of childhood acute lymphoblastic leukemia and is active against brain tumors, bladder cancer, and breast cancer. Its antitumor activity is related to stabilization of the cleavable complex between topoisomerase II and DNA, leading to irreversible DNA strand breaks.

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Yes, Teniposide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL452231. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 452548. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.